Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Total Liabilities
Everything the company owes to creditors and other parties.
Faeth Therapeutics, Inc.NASDAQ: FTH
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 265.8% from a year ago
Total liabilities stood at $16.35M at the end of Q2 FY2026, up 265.8% from a year earlier and up 15.2% from the prior quarter. Over 3 fiscal years it compounded at -34.0% a year.
Context
- Total liabilities amounted to 8.6% of total assets at the end of Q2 FY2026, down 5.4 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +265.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.31M USD
- Year-over-year change
- -38.2%
- 4-year CAGR
- -10.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.31M | -38.2% |
| FY2024 | 2024-12-31 | 6.98M | -26.4% |
| FY2023 | 2023-12-31 | 9.48M | -36.7% |
| FY2022 | 2022-12-31 | 14.97M | +123.0% |
| FY2021 | 2021-12-31 | 6.71M | — |
Total Liabilities vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's Jun 2026 total liabilities of $16.35M is the lowest of the 10 companies compared; the peer median is $77.45M.
- Its year-over-year change of +265.8% is the highest of 10, against a peer median of +22.6%.
- Total liabilities amounts to 8.6% of total assets for FTH, versus a peer median of 38.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $544.67M | +43.6% | +150.2% | 83.5% | |
| Jun 2026 | $490.64M | +78.9% | +156.8% | 65.9% | |
| Mar 2026 | $146.03M | -11.0% | +58.4% | 64.1% | |
| Mar 2026 | $86.69M | +126.3% | +5.4% | 8.4% | |
| Jun 2026 | $77.45M | +22.6% | -28.7% | 8.0% | |
| Mar 2026 | $64.28M | -35.1% | -24.6% | 33.4% | |
| Mar 2026 | $59.46M | +56.1% | +42.6% | 49.7% | |
| Mar 2026 | $54.59M | -0.1% | -28.3% | 38.7% | |
| Sep 2026 | $53.29M | +6.4% | -34.5% | 5.2% | |
| Jun 2026 | $16.35M | +265.8% | -34.0% | 8.6% | |
| Peer median (excluding FTH) | $77.45M | +22.6% | +5.4% | 38.7% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.16M | 17.8M | 13.01M | 9.99M | 8.67M |
| Short-term Investments | 140.46M | 89.32M | 52.75M | 31.34M | 12.52M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 374K | 344K | 325K | 120K | 92K |
| Total Current Assets | 148.54M | 108.59M | 67.25M | 41.93M | 21.51M |
| Property, Plant & Equipment (Net) | 4.64M | 9.72M | 7.04M | 3.38M | 1.38M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 39K | 63K | 86K | 48K | 18K |
| Total Non-current Assets | 4.68M | 9.79M | 7.12M | 3.43M | 1.4M |
| Total Assets | 153.23M | 118.38M | 74.37M | 45.36M | 22.9M |
| Account Payables | 2.46M | 4.47M | 1.69M | 244K | 689K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 2.01M | 1.4M |
| Total Current Liabilities | 4.89M | 9.07M | 5.64M | 5.45M | 4.25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 59K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 149K | 0 | 67K | 0 | 0 |
| Total Non-current Liabilities | 1.82M | 5.9M | 3.84M | 1.53M | 59K |
| Total Liabilities | 6.71M | 14.97M | 9.48M | 6.98M | 4.31M |
| Common Stock | 3K | 3K | 3K | 3K | 0 |
| Retained Earnings | (149.21M) | (197.79M) | (231.9M) | (262.05M) | (283.14M) |
| Accumulated OCI | (333K) | (1M) | (209K) | (13K) | 1K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 146.51M | 103.41M | 64.9M | 38.39M | 18.59M |
| Total Debt | 2.35M | 8.03M | 6.21M | 3.85M | 1.51M |
| Net Debt | (4.81M) | (9.76M) | (6.8M) | (6.15M) | (7.16M) |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.